Bevacizumab for Graft Rejection

Ophthalmology

Volumn 114, Issue 10, 2007, Pages

  Harooni, Hooman ^a   Reddy, Vandana ^a   Root, Timothy ^a   Ambati, Balamurali ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE ACETATE; TACROLIMUS; TRIAMCINOLONE; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; CASE REPORT; COLON CANCER; CORNEA TRANSPLANTATION; DIABETIC RETINOPATHY; DRUG MECHANISM; GRAFT FAILURE; GRAFT REJECTION; HUMAN; LETTER; MALE; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION;

EID: 34748823112     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.05.016     Document Type: Letter

References (5)

1. Weisbrod D.J., Sit M., Naor J., and Slomovic A.R. Outcomes of repeat penetrating keratoplasty and risk factors for graft failure. Cornea 22 (2003) 429-434
2. Chang J.H., Gabison E.E., Kato T., and Azar D.T. Corneal neovascularization. Current Opin Ophthalmol 12 (2001) 242-249
3. Ferrara N., Hillan K.J., and Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333 (2005) 328-335
4. Bashshur Z.F., Bazarbachi A., Schakal A., et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9
5. Oshima Y., Sakaguchi H., Gomi F., and Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142 (2006) 155-158